International Clinical Trial: Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma: A Multicenter Randomized Clinical Phase 3 Trial

Geneva, June 22 -- International Clinical Trials Registry received information related to the study (ChiCTR2600126593) titled 'Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma: A Multicenter Randomized Clinical Phase 3 Trial' on June 11.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Fifth Affiliated Hospital, Sun Yat-Sen University

Condition: Oligometastatic Nasopharyngeal Carcinoma

Intervention: Experimental Group:SBRT in combination with PD-1 inhibitor immunotherapy

Recruitment Status: Recruiting

Phase: N/A

Date of First Enrollment: 2021-08-30

Target Sample Size: Experimental Group:94;Control Group:94;

Countries of Recruitment:...